Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Colorcon
Boehringer Ingelheim
Harvard Business School

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Oteracil


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Oteracil?

Oteracil is an investigational drug.

There have been 80 clinical trials for Oteracil. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Yonsei University.

There are four hundred and thirty-six US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Oteracil
TitleSponsorPhase
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerSuzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2/Phase 3
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction CancOno Pharmaceutical Co. LtdPhase 3
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric JunctionXuefei.WangPhase 2

See all Oteracil clinical trials

Clinical Trial Summary for Oteracil

Top disease conditions for Oteracil
Top clinical trial sponsors for Oteracil

See all Oteracil clinical trials

US Patents for Oteracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Oteracil ⤷  Sign up for a Free Trial Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Sign up for a Free Trial
Oteracil ⤷  Sign up for a Free Trial Aryl-cyanoguanidine compounds Bayer Pharma Aktiengesellschaft (Berlin, DE) ⤷  Sign up for a Free Trial
Oteracil ⤷  Sign up for a Free Trial Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP) ⤷  Sign up for a Free Trial
Oteracil ⤷  Sign up for a Free Trial Multimodal silica-based nanoparticles ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Oteracil

Drugname Country Document Number Estimated Expiration Related US Patent
Oteracil Argentina AR098961 2033-12-23 ⤷  Sign up for a Free Trial
Oteracil Australia AU2014372833 2033-12-23 ⤷  Sign up for a Free Trial
Oteracil Canada CA2934617 2033-12-23 ⤷  Sign up for a Free Trial
Oteracil China CN106163568 2033-12-23 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Colorcon
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.